Alcon Names Stephen S. Lane, MD, as Chief Medical Officer

May 12, 2017: By Joan McKenna
Stephen Lane, MD

Stephen Lane, MD

Ophthalmologist Stephen S. Lane, MD, will join Alcon as chief medical officer and global head of clinical strategy, as of June 1, the company announced May 8.

Lane specializes in cataract surgery, cornea/external diseases, anterior segment surgery, LASIK, and refractive surgery.

He is a founding partner of Associated Eye Care of Stillwater, Minnesota, and was president of the American Society of Cataract and Refractive Surgery (ASCRS) from 2003 to 2004.

Alcon, the Fort Worth, Texas-based eye care division of Switzerland’s Novartis, said Lane’s experience in ophthalmic surgery, contact lens and intraocular lens development, clinical trial design and execution, and the regulatory process should complement Alcon’s strategy.

Lane succeeds Peter Richardson, MD, in the role.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Refocus Completes PMA Application for VisAbility as Treatment for Presbyopia

Novaliq’s NovaTears+Omega-3 Approved in Europe for Dry Eye

CooperVision Acquires Paragon Vision Sciences for $80 Million

AYOXXA Biosystems Launches Test for Biomarkers in Retinal Disease

Glaukos Announces New Patent for Glaucoma Stent Implanted in Schlemm’s Canal

Fortress Biotech Forms Tamid Bio Subsidiary; Lead Candidate is Ophthalmic Gene Therapy for MPS I

Samsung Launches App that Adjusts QLED TV Settings for Color-blind Viewers

Solar Eclipse Burns Crescent Wound in Woman’s Unprotected Retina

US Judge Refuses to Dismiss Allergan Suit against Imprimis

BioLight Sells IOPtima to Chengdu Kanghong Pharmaceutical Group for $56 Million

Regeneron Ending Eylea, Nesvacumab Combo Program

UK Retinal Drugmaker Exonate Forms Clinical Advisory Board

US FDA Approves RxSight’s Light Adjustable Lens and Light Delivery Device

EMA to Move to Amsterdam due to Brexit

First Subject Dosed in Nevakar’s Phase III Trial of NVK-002 for Myopia in Children

ProQR Doses First Patient in Phase I/II Trial for Leber’s Congenital Amaurosis 10

Aston EyeTech Raises $6.6 Million in Series A Equity Round

Ellex Raises $17.7 Million in Private Placement

Genentech’s Lampalizumab Fails Second Phase III Study in Geographic Atrophy

Judge Declares Mistrial in Corruption Trial of Melgen, Menendez

Coming soon

2017 Dry Eye Products Report: A Global Market Analysis for 2016 to 2022